Imprime PGG TM for Injection

BIOLOGICAL2 trials

Sponsors

HiberCell, Inc.

Conditions

Healthy

Phase 1

Phase I/II, Randomized, Double-Blind, Study of the Progenitor Cell Mobilizing Effects of Imprime PGG™ Injection Administered at Varied Dosing Regimens With G-CSF Versus G-CSF Alone

CompletedNCT00542529

HiberCell, Inc.Healthy

Start: 2006-11-30End: 2006-12-31Updated: 2007-10-11

Multiple-Dose, Dose-Escalation Safety, Pharmacodynamics, and Pharmacokinetics Study of Imprime PGG™ Injection

CompletedNCT00542464

HiberCell, Inc.Healthy

Start: 2006-05-31End: 2006-09-30Updated: 2007-10-11